Friederike Holze

Postdoctoral Fellow at Copenhagen University Hospital

Data updated

Papers

36 publications

Trials

0 clinical trials

Research Footprint

Friederike Holze appears in 36 tracked papers (2019–2026), most studied alongside LSD, Psilocybin and MDMA, across Healthy Volunteers, Anxiety Disorders and Depressive Disorders.

Most-cited paper: Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study (285 citations).

Frequent co-authors: Matthias Liechti, Patrick Vizeli and Lukas Ley.

Background & Research

Dr. Friederike Holze is a researcher dedicated to understanding the pharmacology of psychedelics in humans. Her work at the University of Basel and Copenhagen University Hospital focuses on dose-finding studies and the safety and efficacy of LSD. She utilizes PET and fMRI to map the effects of these substances on brain activity and has supervised hundreds of controlled psychedelic sessions.

Key Impact

Specializes in the clinical pharmacology and dose-response dynamics of LSD and other classic psychedelics.

36

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

44 collaborators· click a node to visit their profile

Full network →

Compounds

LSDPsilocybinMDMADMTMescalinePlacebo2C-X

Topics

Healthy VolunteersAnxiety DisordersDepressive DisordersMedicinal Chemistry & Drug DevelopmentNeuroimaging & Brain MeasuresChronic PainMicrodosingSafety & Risk ManagementHeadache Disorders (Cluster & Migraine)Palliative & End-of-Life DistressPersonality & Trait FactorsSubstance Use Disorders (SUD)Neurocognitive DisordersPTSDInterpersonal Functioning & Social ConnectednessSuicidalitySchizophreniaPublic Health, Prevention & Behaviour ChangeImmunology & InflammationMajor Depressive Disorder (MDD)Set & SettingTreatment-Resistant Depression (TRD)Personality Disorders

Top Collaborators

Affiliations

Institutions, companies, and organisations Friederike Holze is associated with.

University of Basel

academic

The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.

View stakeholder →